Granules India Secures Sole First-to-File ANDA Status for Sodium Oxybate Extended-Release Oral Suspension

On July 6, 2026, Granules India Limited announced it obtained Sole First-to-File (FTF) status from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Sodium Oxybate Extended-Release for Oral Suspension. The product is the generic equivalent of LUMRYZ®, a branded treatment for cataplexy and excessive daytime sleepiness in patients with narcolepsy. This FTF designation typically grants the first applicant 180 days of market exclusivity upon approval, potentially allowing Granules to capture a substantial share before competitors enter. It is the company’s second Sole FTF success — following Amphetamine Extended-Release Tablets (generic Dyanavel XR®) — and highlights a growing pipeline of complex, hard‑to‑replicate products aimed at the U.S. market. [Announcement Details]

Granules India is a vertically integrated pharmaceutical manufacturer headquartered in Hyderabad. It produces active pharmaceutical ingredients (APIs), formulation intermediates, and finished dosage forms, with the majority of revenue coming from finished tablets and capsules sold to generic and branded drug companies across North America, Europe, and other regulated markets. The company has a particular focus on controlled substances and complex formulations, including an established U.S. manufacturing and commercial footprint.

Understanding the Sole First-to-File Advantage

A Sole First-to-File designation means Granules was the first applicant to submit a substantially complete ANDA for a generic version of LUMRYZ®. While the press release does not explicitly confirm a paragraph IV patent challenge — the typical path for FTF status — the designation signals that the company was first in line and may be entitled to 180 days of exclusivity once the FDA approves the product. During that window, no other generic Sodium Oxybate extended-release oral suspension could be approved, creating a temporary monopoly. [Announcement Details]

The drug itself is a Schedule III controlled substance, adding regulatory complexity. Granules already operates a controlled‑substance manufacturing platform in the U.S. and, according to management, ranked 4th among all U.S. generic companies by sales value in the controlled‑substance space as of the May 2026 earnings call. That existing infrastructure — including DEA quota access — is directly relevant to bringing a product like this to market.

A Deliberate Bet on Complex Generics

Management has been telegraphing a strategic pivot toward high‑barrier products for several years, and the Sodium Oxybate FTF is a tangible output. In the May 2026 earnings call — the last detailed commentary before this announcement — Chairman Dr. Krishna Prasad Chigurupati described FY’26 as a year of “continued and intentional evolution of the product portfolio. The company accelerated its shift towards more complex and differentiated products. The transition is already strengthening competitive positioning and opening pathways for higher-value opportunities, including potential first-to-file filing.”

The numbers bear this out. Gross margin expanded from 50% in FY’22 to 65% in FY’26 — a 1,500‑basis‑point improvement — which CFO Mukesh Surana directly attributed to “a sustained shift towards complex generics and higher contribution from value‑added formulations.” R&D spending reached ₹2,853 million (5.3% of sales) in FY’26, focused on CII/ADHD, oncology, MUPS, and other high‑barrier formulations. Executive Director Priyanka Chigurupati highlighted that “the quality of filings are significantly improving. They’re moving more and more towards complex products, more in the controlled space and oncology space, 2 big drivers for us. And we have a few first-to-files targeted, a lot of NCE-1 targeted, and we plan to be there on day 1 with a very, very good value proposition.”

Granules’ U.S. subsidiary, GPI (Virginia), has scaled from the 74th to the 27th position among all U.S. generic companies by sales value over four years, providing the commercial backbone to launch another controlled substance. The company filed six U.S. ANDAs in FY’26, with complex generics accounting for “a meaningful share,” reinforcing the pipeline direction.

The Regulatory Overhang: Gagillapur and Approval Timing

One key watchpoint is manufacturing‑site readiness. In the May 2026 call, management disclosed that 9 ANDA applications are pending clearance from the Gagillapur facility, which is under a U.S. FDA warning letter. Chairman Chigurupati stated that “the focus in the year ahead remains unambiguous: achieving sustained U.S. FDA readiness in Gagillapur.” While the company says it is “ready for an audit,” the timing of any FDA reinspection is unknown; Priyanka Chigurupati noted, “we can’t estimate when they would walk in… there has been no communication from the FDA.” Granules has not specified which site would manufacture Sodium Oxybate ER, so the Gagillapur status could become a gating factor if that facility is involved.

The company also has not provided a specific timeline for approval or launch of this ANDA, and no details of patent litigation or settlements related to LUMRYZ® have been publicly disclosed. This means the exact duration and start of any exclusivity window remain uncertain. [Announcement Details; 3]

What’s Worth Watching

- Commercial execution of the first FTF: The earlier Amphetamine ER Sole FTF ANDA has tentative FDA approval. Final approval and launch would provide a real‑world test of Granules’ ability to convert FTF wins into revenue.
- Gagillapur reinspection: Any communication from the FDA on a site review — and the subsequent approval of pending applications — would lift a significant regulatory overhang for the entire pipeline.
- Complex‑portfolio margin effects: As more complex generics reach the market, the company’s gross margin trajectory could validate the thesis that higher‑barrier products deliver sustainably superior profitability.

All information in this note is drawn from Granules India’s own filings, the July 6, 2026 press release, and the May 2026 earnings‑call transcript. No investment recommendation is made.

---

Sources

1 Financial statement analysis
2 Earnings-call transcript, May 2026
3 Announcement under Regulation 30 (LODR)-Press Release / Media Release
4 announcement_category · neutral · value 0.550000
5 Granules India Ltd-$ - 532482 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
6 Granules India Ltd-$ - 532482 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
7 Granules India Ltd-$ - 532482 - Announcement under Regulation 30 (LODR)-Press Release / Media Release